G
Gad Getz
Researcher at Broad Institute
Publications - 627
Citations - 309042
Gad Getz is an academic researcher from Broad Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 189, co-authored 520 publications receiving 247560 citations. Previous affiliations of Gad Getz include University of Colorado Denver & University of California, San Diego.
Papers
More filters
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin,Annabelle J. Anandappa,Jing Sun,Itay Tirosh,Nathan Mathewson,Shuqiang Li,Giacomo Oliveira,Anita Giobbie-Hurder,Kristen Felt,Evisa Gjini,Sachet A. Shukla,Zhuting Hu,Letitia Li,Phuong M. Le,Rosa Lundbye Allesøe,Rosa Lundbye Allesøe,Alyssa R. Richman,Monika S. Kowalczyk,Sara Abdelrahman,Jack Geduldig,Sarah Charbonneau,Kristine Pelton,J. Bryan Iorgulescu,Liudmila Elagina,Wandi Zhang,Oriol Olive,Christine McCluskey,Lars Rønn Olsen,Jonathan Stevens,William J. Lane,Andres M. Salazar,Heather Daley,Patrick Y. Wen,E. Antonio Chiocca,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Gad Getz,Eric S. Lander,Aviv Regev,Jerome Ritz,Donna Neuberg,Scott J. Rodig,Keith L. Ligon,Mario L. Suvà,Kai W. Wucherpfennig,Nir Hacohen,Edward F. Fritsch,Kenneth J. Livak,Patrick A. Ott,Catherine J. Wu,David A. Reardon +51 more
TL;DR: In this article, the authors used personalized neoantigen-targeting vaccines to immunize patients newly diagnosed with glioblastoma following surgical resection and conventional radiotherapy in a phase I/Ib study.
Proceedings ArticleDOI
Abstract 5631: Personal neoantigen-targeting vaccination generates neoepitope-specific T cell responses in tumors of patients with glioblastoma
Derin B. Keskin,Itay Tirosh,Annabelle J. Anandappa,Jing Sun,Nathan Mathewson,Sachet A. Shukla,Evisa Gjini,Shuqiang Li,Letitia Li,Anita Giobbie-Hurder,Phuong M. Le,Zhuting Hu,Wandi Zhang,Oriol Olive,Christine McCluskey,Heather Daley,Patrick Y. Wen,Antonio E. Chiocca,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Gad Getz,Donna Neuberg,Jerome Ritz,Eric S. Lander,Aviv Regev,Kai W. Wucherpfennig,Mario L. Suvà,Edward F. Fritsch,Rodig Scott,Keith L. Ligon,Kenneth J. Livak,Hacohen Nir,Patrick A. Ott,Catherine J. Wu,David A. Reardon +35 more
TL;DR: To the knowledge, this phase 1/1b study provides the first evidence that tumor specific T cells can traffic from the periphery into glioblastoma tumors and that neoantigen-targeting vaccines can favorably alter the tumor immune milieu of gliOBlastoma.
Journal ArticleDOI
Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression
Mark Bustoros,Jihye Park,Karma Salem,Chia Jen Liu,Chia Jen Liu,Marzia Capelletti,Daisy Huynh,Yu-Tzu Tai,Tarek H. Mouhieddine,Samuel S. Freeman,Gavin Ha,Justin Rhoades,Sarah C. Reed,Gregory Gydush,Denisse Rotem,Adriana Perilla Glen,Patrick Henrick,Aaron M. Caola,Bradley Rivotto,Alexandra Savell,Kimberly Noonan,Kaitlen Reyes,Antonio Sacco,Cody J. Boehner,Cody J. Boehner,Houry Leblebjian,David Liu,Elizabeth A. Morgan,Aldo M. Roccaro,Claudia E. Paba-Prada,Eliezer M. Van Allen,Christopher Love,Viktor A. Adalsteinsson,Jacob P. Laubach,Robert L. Schlossman,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson,Shaji Kumar,Gad Getz,Irene M. Ghobrial,Salomon Manier +41 more
TL;DR: Next generation sequencing methods used in this study suggest that specific genomic alterations are associated with HRSMM and could potentially be predictive of the risk to progression in SMM patients.
Journal ArticleDOI
Novel Putative Driver Gene Mutations in Chronic Lymphocytic Leukemia (CLL): Results from a Combined Analysis of Whole-Exome Sequencing of 262 Primary CLL Samples
Dan A. Landau,Dan A. Landau,Chip Stewart,Johannes G. Reiter,Johannes G. Reiter,Michael S. Lawrence,Carrie Sougnez,Jennifer R. Brown,Armando López-Guillermo,Stacey Gabriel,Eric S. Lander,Donna Neuberg,Carlos López-Otín,Elias Campo,Gad Getz,Catherine J. Wu,Catherine J. Wu +16 more
TL;DR: The larger size of this cohort enabled the separate application of the somatic mutation discovery process to samples with mutated or unmutated IGHV, and identified 40 recurrently mutated genes in this cohort, including 22 of 25 previously identified recurrently mutations in CLL.
Journal ArticleDOI
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Arvind Ravi,Matthew D. Hellmann,Monica Arniella,Mark Holton,Samuel S. Freeman,Vivek Naranbhai,Chip Stewart,Ignaty Leshchiner,Jaegil Kim,Yoshitaka Akiyama,Aaron T. Griffin,Natalie I. Vokes,Mustafa Sakhi,Vashine Kamesan,Hira Rizvi,Biagio Ricciuti,Patrick M. Forde,Valsamo Anagnostou,Jonathan W. Riess,Don L. Gibbons,Nathan A. Pennell,Vamsidhar Velcheti,Subba R. Digumarthy,Mari Mino-Kenudson,Andrea Califano,John V. Heymach,Roy S. Herbst,Julie R. Brahmer,Kurt A. Schalper,Victor E. Velculescu,Brian Henick,Naiyer A. Rizvi,Pasi A. Jänne,Mark M. Awad,Andrew Chow,Benjamin Greenbaum,Marta Luksza,Alice T. Shaw,Jedd D. Wolchok,Nir Hacohen,Gad Getz,Justin F. Gainor +41 more
TL;DR: In this article , a joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with non-small cell lung cancer treated with anti-PD-(L)1/PD-L1 therapy, along with matched clinical response annotation is presented.